Literature DB >> 27044545

Oxadiazoles Have Butyrate-Specific Conditional Activity against Mycobacterium tuberculosis.

Julie V Early1, Allen Casey1, Maria Angeles Martinez-Grau2, Isabel C Gonzalez Valcarcel3, Michal Vieth3, Juliane Ollinger1, Mai Ann Bailey1, Torey Alling1, Megan Files1, Yulia Ovechkina1, Tanya Parish4.   

Abstract

Mycobacterium tuberculosis is a global pathogen of huge importance which can adapt to several host niche environments in which carbon source availability is likely to vary. We developed and ran a phenotypic screen using butyrate as the sole carbon source to be more reflective of the host lung environment. We screened a library of ∼87,000 small compounds and identified compounds which demonstrated good antitubercular activity against M. tuberculosis grown with butyrate but not with glucose as the carbon source. Among the hits, we identified an oxadiazole series (six compounds) which had specific activity against M. tuberculosis but which lacked cytotoxicity against mammalian cells.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27044545      PMCID: PMC4879361          DOI: 10.1128/AAC.02896-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

1.  Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values.

Authors:  R J Lambert; J Pearson
Journal:  J Appl Microbiol       Date:  2000-05       Impact factor: 3.772

2.  Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS).

Authors:  J E Graham; J E Clark-Curtiss
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity.

Authors:  S P Crouch; R Kozlowski; K J Slater; J Fletcher
Journal:  J Immunol Methods       Date:  1993-03-15       Impact factor: 2.303

4.  Antituberculosis activity of the molecular libraries screening center network library.

Authors:  Joseph A Maddry; Subramaniam Ananthan; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Clinton Maddox; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Melinda I Sosa; E Lucile White; Wei Zhang
Journal:  Tuberculosis (Edinb)       Date:  2009-09-26       Impact factor: 3.131

5.  pckA-deficient Mycobacterium bovis BCG shows attenuated virulence in mice and in macrophages.

Authors:  Keyi Liu; Jinzhi Yu; David G Russell
Journal:  Microbiology       Date:  2003-07       Impact factor: 2.777

Review 6.  Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Authors:  Scott G Franzblau; Mary Ann DeGroote; Sang Hyun Cho; Koen Andries; Eric Nuermberger; Ian M Orme; Khisimuzi Mdluli; Iñigo Angulo-Barturen; Thomas Dick; Veronique Dartois; Anne J Lenaerts
Journal:  Tuberculosis (Edinb)       Date:  2012-08-30       Impact factor: 3.131

7.  Comparison of 3 cytotoxicity screening assays and their application to the selection of novel antibacterial hits.

Authors:  Luka Peternel; Miha Kotnik; Andrej Prezelj; Uros Urleb
Journal:  J Biomol Screen       Date:  2009-02-04

8.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Authors:  Kevin Pethe; Patricia C Sequeira; Sanjay Agarwalla; Kyu Rhee; Kelli Kuhen; Wai Yee Phong; Viral Patel; David Beer; John R Walker; Jeyaraj Duraiswamy; Jan Jiricek; Thomas H Keller; Arnab Chatterjee; Mai Ping Tan; Manjunatha Ujjini; Srinivasa P S Rao; Luis Camacho; Pablo Bifani; Puiying A Mak; Ida Ma; S Whitney Barnes; Zhong Chen; David Plouffe; Pamela Thayalan; Seow Hwee Ng; Melvin Au; Boon Heng Lee; Bee Huat Tan; Sindhu Ravindran; Mahesh Nanjundappa; Xiuhua Lin; Anne Goh; Suresh B Lakshminarayana; Carolyn Shoen; Michael Cynamon; Barry Kreiswirth; Veronique Dartois; Eric C Peters; Richard Glynne; Sydney Brenner; Thomas Dick
Journal:  Nat Commun       Date:  2010-08-24       Impact factor: 14.919

9.  A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.

Authors:  Juliane Ollinger; Mai Ann Bailey; Garrett C Moraski; Allen Casey; Stephanie Florio; Torey Alling; Marvin J Miller; Tanya Parish
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

10.  The effect of organic acids on mammalian tubercle bacilli.

Authors:  R J DUBOS
Journal:  J Exp Med       Date:  1950-10-01       Impact factor: 14.307

View more
  9 in total

1.  Determining Minimum Inhibitory Concentrations in Liquid Cultures or on Solid Medium.

Authors:  Qinglan Wang; Helena I M Boshoff
Journal:  Methods Mol Biol       Date:  2021

2.  Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery.

Authors:  Krupa Naran; Atica Moosa; Clifton E Barry; Helena I M Boshoff; Valerie Mizrahi; Digby F Warner
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

3.  Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis.

Authors:  Maria Angeles Martinez-Grau; Isabel C Gonzalez Valcarcel; Julie V Early; Richard Klaus Gessner; Candice Soares de Melo; Eva Maria Martin de la Nava; Aaron Korkegian; Yulia Ovechkina; Lindsay Flint; Anisa Gravelle; Jeff W Cramer; Prashant V Desai; Leslie J Street; Joshua Odingo; Thierry Masquelin; Kelly Chibale; Tanya Parish
Journal:  Bioorg Med Chem Lett       Date:  2018-04-13       Impact factor: 2.823

4.  Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia.

Authors:  Kristina Kesely; Panae Noomuna; Michal Vieth; Philip Hipskind; Kasturi Haldar; Antonella Pantaleo; Francesco Turrini; Philip S Low
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

5.  Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.

Authors:  Jonah Larkins-Ford; Talia Greenstein; Nhi Van; Yonatan N Degefu; Michaela C Olson; Artem Sokolov; Bree B Aldridge
Journal:  Cell Syst       Date:  2021-08-31       Impact factor: 10.304

Review 6.  Hit Generation in TB Drug Discovery: From Genome to Granuloma.

Authors:  Tianao Yuan; Nicole S Sampson
Journal:  Chem Rev       Date:  2018-01-31       Impact factor: 60.622

7.  Mycobacterium tuberculosis requires glyoxylate shunt and reverse methylcitrate cycle for lactate and pyruvate metabolism.

Authors:  Agnese Serafini; Lendl Tan; Stuart Horswell; Steven Howell; Daniel J Greenwood; Deborah M Hunt; Minh-Duy Phan; Mark Schembri; Mercedes Monteleone; Christine R Montague; Warwick Britton; Acely Garza-Garcia; Ambrosius P Snijders; Brian VanderVen; Maximiliano G Gutierrez; Nicholas P West; Luiz Pedro S de Carvalho
Journal:  Mol Microbiol       Date:  2019-08-23       Impact factor: 3.501

8.  Deletion of Rv2571c confers resistance to arylamide compounds in Mycobacterium tuberculosis.

Authors:  Catherine D Shelton; Matthew B McNeil; Julie V Early; Thomas R Ioerger; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.938

Review 9.  Evolution of Antibacterial Drug Screening Methods: Current Prospects for Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Microorganisms       Date:  2021-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.